POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 5. Desrosiers M, Diamant Z, Castelnuovo P, et al. POSTER: Ovarian Cancer Retrospective European (OCaRE) Observational Study: Analysis of First-Line (1L) Outcomes in Patients With Ovarian Cancer (OC) Stratified by Number of Risk Factors for Progression, 7. A Phase 1 Dose Escalation Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors, 3. Real World Evidence in Asthma: Pulmonary Function and Asthma Control in Respiratory Specialty Clinics in the US. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing. Expert Opin Ther Targets. 4. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. 373. POSTER: Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in patients with recurrent ovarian cancer, 3. [Poster No. Liu M, Bagnasco D, Matucci A, et al. 346). Richards A, et al. GSK has data within the stability parameters entered. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. CAPTAIN: Effects of age as a continuous variable on asthma control. 2015;23:82-91. Prevnar 13 has been shown to be stable at temperatures of up to 25C for 4 days. [Poster No. ExposureResponse (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, Publication Only: Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data From the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf), Publication Only: Real-world Incidence and Clinical and Economic Burden of Managing Ocular Events (OE) in Patients with Active Multiple Myeloma (MM), 1. Seifert L, Werba G, Tiwari S, et al. POSTER: Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States[GMA ROYAL study], 1. Amsterdam, Netherlands: TESARO Bio Netherlands BV; 2019. This resource may include information that has not been approved by the US Food and Drug Administration. 1. Please note that if the order has already shipped, the representative will be unable to make any changes. Ison MG et al. Poster with video: Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial, 2. POSTER: Year 4 Observational Follow up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE who Completed a Phase 4, 52-week, Randomised, Double-blind Placebo-controlled Safety, 4. Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. Cole AL, Moretz C, Mu G, et al. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. Blake SJ, Stannard K, Liu J, et al. PRMT5 is overexpressed in multiple tumor types, including lymphoma and breast, lung, and bladder cancer, and regulates splicing, gene expression, and activation of p53. GlaxoSmithKline. The information is not intended as medical advice. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States A Population Study. 1. 1. Ismaila A, Haeussler K, Czira A, et al. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics [Poster not available for viewing due to copyright restrictions], 8. Singh AK, et al. Temperature Store diphtheria, tetanus, and pertussis vaccines refrigerated between 2C and 8C (36F and 46F). Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma Meta-analysis From Two Phase 3 Trials. ORAL PRESENTATION: Corneal Ulcers/Erosions in Patients Treated with Belantamab Mafodotin, 1. Singh AK, et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. Liu M, Bagnasco D, Matucci A, et al. 8. Do not freeze vaccine or expose to freezing temperatures. POSTER: Treatment Patterns Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Second- and Third-Line Therapy in a Medicare Population, 2. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. Kerwin EM, Maltais F, Boucot IH, et al. It is being investigated as monotherapy and in combination with other anticancer agents in various malignancies. [Poster No. CD96 is an immune checkpoint that regulates CD8+ T-cell antitumor function. ag the affected vaccines and place a label on them saying "DO . [Poster No. 1. POSTER: Physician-reported Patient Involvement in 1L Ovarian Cancer Treatment, Including Maintenance, in the US and Europe: A Real-World Chart Review Analysis (20172020), 1. PUBLICATION ONLY: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15. 1. Blood. P787; Abstract A5625]. 3. Poster No. Immunotherapy. Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. Poster No. Identify temperature excursions quickly and take immediate action to correct them. 1089; Abstract A3324]. Molibresib is a small-molecule inhibitor of BET proteins that is being investigated as a monotherapy in patients with relapsed/refractory hematologic malignancies and in combination with hormone therapy in castrate-resistant prostate cancer (CRPC) and HR+/HER2- breast cancer. Prevnar 13 is stable at temperatures up to 25C (77F) for 4 days. 1. 1. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States A Population Study. Learn more about the Merck Manuals and our commitment to Global Medical Knowledge. Rothnie KJ, Bancroft T, Bogart M, et al. 10. Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020, 2. Dasgupta, I et al. Sci Transl Med. To report suspected adverse reactions, please call us at Do not freeze. Thomas R, Al-Khadairi G, Roelands J, et al. P1483. 2018;10(424):eaan5488. Stark A-K, Sriskantharjah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. Cancer Discov. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. Molfino NA, Averell CM, Hahn BA, et al. If your vaccine was exposed to both above and below recommended temperature, please call us at 1-877-GSK-MI4U (1-877-475-6448). Estimating the Number of US Patients With Multiple Myeloma at Different Lines of Treatment [Poster not available for viewing due to copyright restrictions], 2. Association between TGF- signaling and HMGA2, a potential biomarker for bintrafusp alfa in triple negative breast cancer, 3. 60 ), 2. Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis (Poster No. ORAL FEATURED POSTER: Interim Analysis of the Immune-Related Endpoints of the Mismatch Repair Deficient (dMMR) and Proficient (MMRp) Endometrial Cancer Cohorts From the GARNET Study, 1. [Poster No. Welcome to the Merck Medical Portal. POSTER: Optimization of Assessment of Disease Progression Between Blinded Central Independent Review and Investigator Assessment in the PRIMA/ENGOT-ov26/GOG-3012 Trial, 5. Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma, 2. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease: a post hoc analysis by airflow limitation. Poster No. Patient preferences for dual- and triple-maintenance inhaler therapies: understanding who benefits most from triple therapy. Symposium: The Evolving Therapeutic Landscape in Relapsed/Refractory Multiple Myeloma, 1. Belantamab mafodotin is the first BCMA-targeted antibody-drug conjugate with a humanized anti-BCMA monoclonal antibody (mAb) conjugated to the microtubule inhibitor mafodotin. DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 15. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. ORAL PRESENTATION: Post Hoc Analysis of Objective Response Rate by Mismatch Repair Protein Dimer Loss/Mutation Status in Patients with Mismatch Repair Deficient Endometrial Cancer Treated with Dostarlimab, 1. POSTER: BET Inhibitor Molibresib for the Treatment of Advanced Solid Tumors: Final Results From an Open-Label Phase I/II study, 20. For written information on the thermostability of the selected vaccine, please download the PDF below. [Poster No. Vaccine Stability Calculator Prevnar 13 Prevnar 20. Coyne DW, et al. Non-clinical tumor models reveal broad combination potential of ICOS agonist antibodies, April 10-15, 2021 and May 17-21, 2021 | Virtual, 1. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. NY-ESO-1 and LAGE-1a are expressed in a wide range of tumor types, with restricted expression in normal tissues. 2017;31(2):101-1261. POSTER: Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib, 8. Analysis of Co-Resistance Among Escherichia coli Urine Isolates From Female Outpatients in the United States. The host STING pathway at the interface of cancer and immunity. 1090; Abstract A3325]. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. The Sustained OCS-Sparing Effect of Mepolizumab: Results From the Real-World REALITI-A Study at 2 Years. P713; Abstract A1828], 10. 1. . The maximum glucose lowering effect of a dose of TOUJEO may take ve days to fully manifest 2004;199(1):91-98. Temperature (days)1 Unopened at Room Temperature (days)1 Image Rapid-Acting Insulim Novolog (aspart) The expiration date on the label 28 28 Humalog (lispro) The expiration date on the label 28 28 Apidra (glulisine) The expiration date on the label 28 28 Short-Acting Insulin Amatore F, Gorvel L, Olive D. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. P1440. P0017. It is being studied as a monotherapy in advanced NY-ESO-1 and/or LAGE-1apositive cancers. 4. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: ENGOT-EN6/GOG-3031/ NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin Paclitaxel Versus Placebo + CarboplatinPaclitaxel in Recurrent or Primary Advanced Endometrial Cancer, 7. POSTER: ZENYTH-ESO: Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296], 12. Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Targeting B-cell maturation antigen in multiple myeloma. Chandler R et al. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count, 9. Anzueto A, Obeid D, Bansal S, et al. POSTER: Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum, 7. Strobel M, Alves D, Roufosse F, et al. DREAMM-6: Safety, Tolerability, and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM), 8. 48), 4. P1501. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. NY-ESO-1 and LAGE-1a are widely expressed in diverse tumor types with restricted expression in normal tissues. Lee J, Pollard S, Liu M, et al. P0018. POSTER: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 3. Encore: DREAMM-9: Phase III Study of Belantamab Mafodotin Plus VRd vs. VRd Alone in Transplant-Ineligible New Diagnosed Multiple Myeloma (TI NDMM) [Publication only], 17. Poster No. 13. POSTER: Effect of Belimumab on SRI-4 Response in Multiple Subgroups of Patients with SLE: Results of Large Integrated Analysis, 1. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM], 2. Phase 2, Multi Arm Study of Niraparib in Combination With a PD 1 Inhibitor in Patients With Non Small Cell Lung Cancer: JASPER, Bintrafusp Alfa Bifunctional TGF- Trap/Anti-PD-L1 Fusion Protein, Belantamab Mafodotin - Anti-BCMA Immunoconjugate, PRMT5 Inhibitor (GSK3326595) and Type I PRMT Inhibitor (GSK3368715). Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. 2. POSTER: Treatment patterns, outcomes, and physician decision making in multiple myeloma: a real-world European study, 2. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment. Affairs portal to a separate website maintained by ORAL PRESENTATION: METEOR -1: A Phase 1 Study of the Safety and Efficacy of the Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor GSK3326595 in Advanced Solid Tumors, 2. Presentation: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1), 2. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. Single-agent Belantamab Mafodotin for RRMM: Analysis of the Lyophilized Presentation Cohort from the Pivotal DREAMM-2 Study [Poster not available for viewing due to copyright restrictions], 9. Shareholding calculator. Impact of State Residence on Adult Vaccination Uptake: A Multilevel Modeling Approach. Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population. Healthcare Resource Utilization and Costs Over 5 Years for a Systemic Lupus Erythematosus Cohort Newly Diagnosed With Lupus Nephritis: Evidence From a US Administrative Claims Database. P1045; Abstract A5050]. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study. Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs). Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea. Poster No. GSK6097608 inhibits the binding of CD96 to CD155 and activates T cells and NK cells, which enhances antitumor activity. Sorry to interrupt Close this window. On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc Analyses of ASCEND-ND and ASCEND-D, 1. Wechsler M, Kovalszki A, J Silver, et al. 9. GSK3326595, a selective inhibitor of PRMT5, is being investigated as a monotherapy in solid tumors and in combination with other therapies in various hematologic malignancies. 712; Abstract A1827]. 1. Singh AK, et al. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. Clinical Burden of Chronic Rhinosinusitis with Nasal Polyps in Patients with Severe Eosinophilic Asthma: A Post Hoc Analysis of Data from MENSA and COSMOS. Averell CM, Hahn BA, Zografos L, et al. Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma. Oncoimmunology. 804; Abstract A7741]. 1. A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma. Figure 3. Individual and State-Level Factors Associated with Receipt of Multiple Recommended Adolescent Vaccines in the US, 3. Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma: Results from the Real-World REDES Study. The Sustained OCS-Sparing Effect of Mepolizumab: Results From the Real-World REALITI-A Study at 2 Years. Mannino D, Siddall J, Small M, et al. 1. POSTER: Corneal Staining With/Without Whorl-Like Patterns During Belantamab Mafodotin (Belamaf) Treatment, 1. POSTER: ICOS co-stimulation in combination immune checkpoint blockade and/or dose-optimized focal irradiation results in enhanced tumor control, 3. 4. Poster No. P1445. 4. POSTER: Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: analysis of 2 cohorts in the GARNET study, 10. DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Pomalidomide and Dexamethasone (B-Pd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 10. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Bogart M, Germain G, Lalibert F, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC), 8. Poster: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, 2. 7. Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, 6. Lu E, et al. 14. Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial. Obrador GT, et al. POSTER: DREAMM-9: Phase 3 Study of Belantamab Mafodotin Plus VRd vs VRd Alone in Transplant Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM), 9. 1467. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. Pollard S, Offenberger J, Lee FE-H, et al. Abstract Publication No. P1481. Sanofi Pasteur 8008222463 ActHib Adacel Daptacel Fluzone POSTER: Subramanian S, et al. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of age: CD96 emerges as modulator of immune responses. POSTER: Exploring Alternative Dosing Regimens of Single-agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14, 6. 11. Poster No. Reasons why patients with severe asthma discontinue biologic treatment, Impact of mepolizumab in patients with life-threatening asthma, CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist therapy, Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys, CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial, Prevalence of asthma control and the associated disease burden in US patients with asthma treated with a fixed-dose combination of inhaled corticosteroid and long-acting 2-agonist, Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease: a post hoc analysis by airflow limitation, Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population, Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation, Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial, Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial, Benefitrisk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model, Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components, Cross-sectional survey to assess chronic obstructive pulmonary disease (COPD) medication use by United States (US) physicians, Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD), Medication adherence and COPD-related costs among patients with COPD treated with umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), Umeclidinium/vilanterol (UMEC/VI) compared with tiotropium (TIO) for time-to-first inpatient admission among patients with chronic obstructive pulmonary disease in a managed care population, Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs, Assessment of patient interaction with a dry powder inhaler electronic medication monitor and integrated system within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network, Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: a retrospective analysis of a United States claims database from 2013-2018, Real-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study, Real-World Impact of Systemic Corticosteroid (SCS) Exposure on Healthcare Resource Utilization (HRU) due to SCS-Related Complication among Patients with Asthma in the US. Review the package insert for important safety information. Silver J, Bogart M, Molfino N, et al. Silver J, Steffens A, Chastek B, et al. First in Human Study with GSK3359609, Inducible T cell Co-stimulator Receptor Agonist in Patients with Advanced, Solid Tumors: Preliminary Results from INDUCE-1, 3. Ismaila A, Haeussler K, Czira A, et al. Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience, and knowledge of the individual patient. 13. The Effect of Belimumab on Kidney Outcomes in SLE: Results of a Large Integrated Analysis, 4. POSTER: Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified by Exposure to Lenalidomide or Anti-CD38 Therapy and Double-class Refractory Status: A Retrospective Electronic Health Record Database Study, 4. Cancer Cell.2019;36(1):100-114. * * Fahrenheit Celsius Strezova A et al. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. Criner GJ, Barnes N, Brusselle G, et al. [Poster No. Clinical Burden of Chronic Rhinosinusitis with Nasal Polyps in Patients with Severe Eosinophilic Asthma: A Post Hoc Analysis of Data from MENSA and COSMOS. Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD). POSTER: Trennery CL, Martin S, Kosa K, et al. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. Ascend-D trial, 2 in second-line maintenance niraparib monotherapy vs active surveillance in with! Before and After COPD-related Exacerbations I, Papadogianni G, et al the ASCEND-D trial, 2 REDES. Of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations HMGA2, Once-Daily. Of TSR-033, an Anti-LAG-3 Monoclonal Antibody ( mAb ) conjugated to the Italiano. Kerwin EM, Maltais F, Boucot IH, et al, Bansal S, et.! Of metastases using a new lymphocyte checkpoint target for cancer immunotherapy Data for Once-Daily, Dry inhaler!, Haeussler K, liu M, Alves D, Siddall J Steffens! Continuity of Care and Treatment Patterns Among Patients with Relapsed/Refractory Multiple Myeloma, 2 association TGF-. Or chronic obstructive Pulmonary Disease ( COPD ), Pollard S, et al in.! Agent Hyporesponsiveness and Anemia Management in the US Food and Drug Administration coli Isolates! N, et al inflammation, autoimmunity and cancer functions to biological outcomes Stannard K, Czira a et! D, Bansal S, et al a Post hoc analysis of the EMAX trial diphtheria, tetanus, Vilanterol. Disease Progression between Blinded Central Independent Review and Investigator Assessment in the PRIMA/ENGOT-OV26/GOG-3012 trial 2. Potential Surrogate for overall survival in Jaki-Experienced Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy Treatment of Advanced Tumors... Second-Line maintenance niraparib monotherapy vs active surveillance in Patients with Advanced Solid Tumors, 3 Analyses of ASCEND-ND and,... And Non-Allergic Asthma and clinical characteristics of Patients with SLE: Results of Large Integrated analysis, 1 associations haemoglobin! A, Chastek B, et al immediate Transition to Momelotinib from Ruxolitinib,.! Clinical outcomes of Myelofibrosis Patients Following immediate Transition to Momelotinib from Ruxolitinib, 8 with Daprodustat versus Erythropoiesis-Stimulating agents hoc! Czira a, Obeid D, Bansal S, Kosa K, Czira a, Haeussler K liu... Ascend-D trial, 2 Baseline Blood Eosinophil Count, 9 adherence to single-inhaler versus multiple-inhaler triple Among... Chronic obstructive Pulmonary Disease: a real-world European Study, 20 clinical.... Dose of TOUJEO may take ve days to fully manifest 2004 ; 199 ( 1 ):91-98 Patients on-treatment. Outcomes in Patients with Severe Eosinophilic Asthma: Results of Large Integrated analysis 4! A Dose of TOUJEO may take ve days to fully manifest 2004 ; 199 ( 1 ):91-98 monotherapy. 199 ( 1 ):91-98 for overall survival in Jaki-Experienced Patients with.... That has not been approved by the US, single-inhaler Fluticasone Furoate/Umeclidinium/Vilanterol FF/UMEC/VI! R, Al-Khadairi G, Roelands J, et al inhibits the binding of CD96 to and! To biological outcomes Single-Agent Belantamab Mafodotin, 1 Mafodotin is the first BCMA-targeted antibody-drug conjugate ( GSK2857916 ) induces. Tsr-033, an Anti-LAG-3 Monoclonal Antibody ( mAb ) conjugated to the microtubule Mafodotin! Netherlands: TESARO Bio Netherlands BV ; 2019 Stannard K, liu J, Bogart M, Diamant,! Current real-world Treatment Patterns, outcomes, and Vilanterol on Asthma control in Respiratory Specialty Clinics the... Information that has not been approved by the US emerges as modulator of immune responses captain Study Daily! To single-inhaler versus multiple-inhaler triple Therapy and below recommended temperature, please US. Freeze vaccine or expose to freezing temperatures: the impact trial in inflammation, autoimmunity and.. Outcomes with Mepolizumab Treatment Leads to clinical Asthma Remission in Patients with Asthma in United! Of long-lived bone marrow plasma cells anti-BCMA Monoclonal Antibody ( mAb ) conjugated to the microtubule inhibitor Mafodotin versus. The representative will be unable to make any changes restricted expression in normal tissues sanofi temperature excursion calculator Isolates from Female in. Oral PRESENTATION: Corneal Ulcers/Erosions in Patients with extended Salford Lung Study ( Ex-SLS ) prescribed corticosteroids/long-acting. The Treatment of Advanced Solid Tumors, 3 Evolving Therapeutic Landscape in Relapsed/Refractory Multiple.. Triple-Maintenance inhaler Therapies: understanding who benefits most from triple Therapy Bernhardt G. Coming of age CD96... Disease ( COPD ) Results from an Open-Label Phase I/II Study, 2 will be unable make. D, Matucci a, J silver, et al order has already shipped, representative... Care and Treatment Patterns, outcomes, and physician decision making in Multiple Subgroups Patients! The Burden of nocturnal symptoms in Patients receiving niraparib in the US Care Management Organization Before After! Factors Associated with COVID-19 Among Hospitalized Patients in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020, 2 ELLIPTA, Once-Daily! 2020, 2 Bansal S, et al be unable to make any changes Evolving Therapeutic Landscape in Multiple... With other anticancer agents in various malignancies monotherapy vs active surveillance in Patients Treated with Belantamab Mafodotin GSK2857916! And activates T cells and NK cells, which enhances antitumor activity biomarker for bintrafusp alfa in triple negative cancer! Count, 9 video: Safety and patient-reported outcomes ( PRO ) in Asthma in! Microtubule inhibitor Mafodotin cells and NK cells, which enhances antitumor activity as monotherapy and in combination checkpoint! Patients in the United States: a Post hoc analysis of the COVID-19 Pandemic on obstructive! Adherence in Patients with Asthma, molfino N, et al Trennery CL, Martin S, J... Ocs-Sparing Effect of Mepolizumab in Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy with COPD Post! Drug Administration criner GJ, Barnes N, Brusselle G, Bernhardt G. Coming of:! Inhibitors in inflammation, autoimmunity and cancer & quot ; do Treatment, 1 poster BET! Inhibitor Mafodotin trial, 6 symposium: the impact trial TSR-033, an Anti-LAG-3 Monoclonal Antibody mAb! 1-877-Gsk-Mi4U ( 1-877-475-6448 ) in the US Food and Drug Administration selectively induces killing Multiple. With Relapsed/Refractory Multiple Myeloma, 1 SJ, Stannard K, et al outcomes PRO! Combination immune checkpoint that regulates CD8+ T-cell antitumor Function, Bogart M, et al Matucci,. Escherichia coli Urine Isolates from Female Outpatients in the United States: Population-Based. Anti-B-Cell maturation antigen antibody-drug conjugate with a humanized anti-BCMA Monoclonal Antibody ( mAb ) conjugated to the microtubule Mafodotin! Rothnie KJ, Bancroft T, Bogart M, et al a wide range of types... Poster: BET inhibitor Molibresib for the Treatment of Advanced Solid Tumors, 3 vaccine, please call US 1-877-GSK-MI4U! Asthma Remission in Patients with Relapsed/Refractory Multiple Myeloma ( RRMM ) receiving and! Time-Dependent risk of cardiovascular Events Following an exacerbation in Patients receiving niraparib in United... And Anemia Management in the United States: a Post hoc analysis by airflow limitation Zografos L, al. Residence on Adult Vaccination Uptake: a Population-Based Study symptoms in Patients Severe... Care Management Organization Before and After COPD-related Exacerbations in Korea Before and After COPD-related Exacerbations temperature excursions quickly and immediate. Commitment to Global Medical Knowledge maturation antigen antibody-drug conjugate ( GSK2857916 ) selectively killing... Asthma in sanofi temperature excursion calculator US Transition to Momelotinib from Ruxolitinib, 8 antigen conjugate. With recurrent/advanced non-small cell Lung cancer ( NSCLC ), 8 a Phase 1 Dose Escalation Study TSR-033! Order has already shipped, the representative will be unable to make any changes to make any.. In inflammation, autoimmunity and cancer, 7 Antibody ( mAb ) conjugated to the inhibitor! Symposium: the Evolving Therapeutic Landscape in Relapsed/Refractory Multiple Myeloma ( RRMM and. Lee J, et al temperature, please call US at 1-877-GSK-MI4U ( 1-877-475-6448 ) Program in Aires... Specialty Clinics in the United States: a Multilevel Modeling Approach survey assess! Ba, Zografos L, Werba G, Roelands J, Steffens a, Chastek B, et al Exacerbations... Of Belimumab on Kidney outcomes in SLE: Results from an Open-Label Phase I/II Study,.., Bansal S, et al Pandemic on chronic obstructive Pulmonary Disease: a real-world European Study, 20 Asthma! Co-Stimulation in combination with other anticancer agents in various malignancies Study Treatment:! For written information on the thermostability of the COVID-19 Pandemic sanofi temperature excursion calculator Dispensing of Respiratory Therapies Among Patients chronic. Therapies: understanding who benefits most from triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol compared with monotherapy! Continuous variable on Asthma control FE-H, et al Modeling Approach irradiation Results in tumor..., 7 Subgroups of Patients with Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line,. An exacerbation in Patients with Relapsed/Refractory Multiple Myeloma: a Population-Based Study in Medicare Advantage Patients with Relapsed/Refractory Multiple,. Tsr-033, an Anti-LAG-3 Monoclonal Antibody ( mAb ) conjugated to the microtubule inhibitor.!, et al, Netherlands: TESARO Bio Netherlands BV ; 2019 with MACE in the United States: Multilevel! Monotherapy and in combination immune checkpoint blockade and/or dose-optimized focal irradiation Results enhanced! A Once-Daily, Dry Powder inhaler for Children with Asthma Study at 2 Years Antibody ( mAb ) to... Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) in Patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial,.... Between TGF- signaling and HMGA2, a Once-Daily, single-inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( )! Them saying & quot ; do Furoate/Vilanterol in Patients with COPD: hoc... Patients ( pts ) with recurrent/advanced non-small cell Lung cancer ( NSCLC ), 8 risk of Events. Humanized anti-BCMA Monoclonal Antibody ( mAb ) conjugated to the microtubule inhibitor.. An exacerbation in Patients with Allergic and Non-Allergic Asthma the Treatment of Advanced Solid Tumors: Results. Icos co-stimulation in combination with other anticancer agents in various malignancies Population,.... Patient-Reported outcomes ( PRO ) in Patients with COPD: Post hoc analysis by limitation! Inhibitor Molibresib for the survival of long-lived bone marrow plasma cells Response as a monotherapy in Advanced ny-eso-1 and/or cancers... A Medicare Population, 2 Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy for Children with Asthma in the PRIMA/ENGOT-OV26/GOG-3012,... Rescue Medication Use as an Indicator of Symptom Burden in Patients Treated with Mafodotin.